Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.60 |
| ▸ | CTSS | P25774 | 4/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7299695 | 1.00 | CTSK (0.60) | CTSKCTSSCTSBCAPN1PTPN1 | |
| SCHEMBL7645794 | 1.00 | CTSK (0.60) | CTSKCTSSCTSBCAPN1PTPN1 | |
| SCHEMBL1094506 | 0.84 | ATM (0.62) | CTSKCTSSCTSBCAPN1ATM | |
| SCHEMBL390555 | 0.84 | ATM (0.62) | CTSKCTSSCTSBCAPN1ATM | |
| SCHEMBL7094 | 0.84 | ATM (0.62) | CTSKCTSSCTSBCAPN1ATM | |
| SCHEMBL11028734 | 0.82 | CTSS (0.62) | CTSKCTSSCTSBPTPN1GABRB1 | |
| SCHEMBL598263 | 0.82 | CTSK (0.61) | CTSKCTSSCTSBPTPN1ATM | |
| SCHEMBL9929938 | 0.82 | CTSK (0.61) | CTSKCTSSCTSBPTPN1ATM | |
| SCHEMBL8523201 | 0.82 | CTSK (0.61) | CTSKCTSSCTSBPTPN1ATM | |
| SCHEMBL3786563 | 0.82 | CTSK (0.64) | CTSKCTSSCTSBATMACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911645-B1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIV LILLE (FR) | 2022-12-07 | — | — | EP | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| US-7087759-B2 | for controlling weight; pyrrolidine or piperidine compounds | THE PROCTER & GAMBLE COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060106059-A1 | Melanocortin receptor ligands | MAZUR WIESLAW A | 2006-05-18 | — | — | US | disclosed |
| EP-1390361-A4 | MELANOCORTIN RECEPTOR LIGANDS | PROCTER & GAMBLE (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6911447-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040224985-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1390361-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030109556-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2002085925-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1184370-A2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| US-6274584-B1 | PEPTIDE DERIVATIVES; BIOAVAILABILITY; ENZYME RESISTANCE; MILK AND WOOL PRODUCTION | NOVO NORDISK A/S (DK) | 2001-08-14 | — | — | US | disclosed |
| US-6127354-A | FOR TREATMENT OF GROWTH DISORDERS OR TO STIMULATE PRODUCTION OF WOOL OR MILK | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5922770-A | NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 1999-07-13 | — | — | US | disclosed |
| EP-0923539-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998003473-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-01-29 | — | — | WO | disclosed |
| EP-0337714-A2 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109556-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | CTSK 2310/4885CTSS 2290/4885CTSB 1962/4885 |
| US-20060106059-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | CTSK 2528/4885CTSS 2541/4885CTSB 1997/4885 |
| US-20040224985-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | CTSK 2310/4885CTSS 2290/4885CTSB 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.